¿ Aclara BioSciences Inc., of Mountain View, Calif., and Caliper Technologies Inc., also of Mountain View, agreed to settle all three lawsuits between them related to patent infringement centered on microfluidics technology. The companies dismissed all claims, cross-licensed the patent families under contest, agreed to a stock payment from Aclara to Caliper with a guaranteed liquidation value after 18 months and agreed to a private resolution process for any future disputes. Caliper also will dismiss its claims against Aclara in its trade secret suit. Aclara will issue 900,000 shares of common stock to Caliper with a guaranteed liquidation price of $36.11 per share for an aggregate value of $32.5 million. Jurors awarded Caliper $52 million in the trade secret misappropriation suit in October. That award later was reduced. (See BioWorld Today, Oct. 31, 2000.)
¿ Ariad Pharmaceuticals Inc., of Cambridge, Mass., said results of in vivo studies demonstrated promising new applications of its Argent-regulated cell-elimination technology for both the treatment and prevention of prostate cancer. The findings are being presented at the Keystone Symposium "Gene Therapy 2001: A Gene Odyssey."
¿ Athersys Inc., of Cleveland, said it entered an agreement with Bristol-Myers Squibb Co., of New York, for access to Athersys' RAGE-VT technology for the production of human cell lines expressing six validated drug targets. The collaboration may be expanded to include up to 50 validated targets. Athersys gets a licensing fee for each cell line as well as milestone payments on the development of candidate therapeutics and royalty payments on sales of resultant products.
¿ Auxein Corp., of Lansing, Mich., and Mycotech Corp., of Butte, Mont., merged to form Emerald BioAgricultrue Corp., of Lansing. Emerald Bio will focus on the development, manufacture and marketing of natural crop-protection and yield-enhancement products.
¿ Biopure Corp., of Cambridge, Mass., held an end-of-Phase-III meeting with the FDA, plans to enter an asset-based debt financing this month for a large-scale manufacturing facility, and is proceeding with its efforts to file a biologics license application this year for Hemopure, an alternative to red blood cell transfusion. Trial results will be reported, the company said, in the first half of the year after the final database has been locked and the study report has been prepared for inclusion in the BLA.
¿ Bio-Technology General Corp., of Iselin, N.J., said The Ferring Group, of Sweden, its European licensee, received approval from the European regulatory authorities for the company's recombinant human growth hormone for treatment of Turner's syndrome. Ferring currently markets the product under the trade name Zomacton.
¿ Caliper Technologies Inc., of Mountain View, Calif., and Structural GenomiX, of San Diego, entered a joint development collaboration focused on high-throughput protein analysis with Caliper's Automated Microfluidics System 90 platform. Financial details were unavailable. Caliper also entered an OEM agreement with Zymark Corp., of Hopkinton, Mass., for volume use and distribution of Zymark's Twister Universal Microplate Handler, a key component of Caliper's LabChip high-throughput screening systems. Financial terms were also undisclosed.
¿ Cambridge NeuroScience Inc., of Norwood, Mass., received a two-year Phase II Small Business Innovation Research grant for up to $860,000 from the National Institute of Neurological Diseases and Stroke for identification and development of drugs to treat peripheral neuropathies. The first-year support could reach $436,000.
¿ Cepheid Inc., of Sunnyvale, Calif., signed a multiyear agreement with Fisher Scientific International Inc., of Hampton, N.H., to market the Cepheid Smart Cycler system in the life science research market in Canada. The Smart Cycler is a rapid thermal cycler.
¿ Chiron Corp., of Emeryville, Calif., said it will sell its gene therapy manufacturing facility to Cell Genesys Inc., of Foster City, Calif., for $4.8 million. Cell Genesys will take over Chiron's lease on the San Diego facility. The transaction includes no product rights.
¿ Ciphergen Biosystems Inc., of Fremont, Calif., said its preliminary revenue forecast for the fourth quarter of 2000 will be about $3 million below previous expectations, or 10 percent to 15 percent lower. Results for the year indicate revenues for Ciphergen will be about $9 million, an 80 percent increase over 1999. Ciphergen's stock (NASDAQ:CIPH) fell 30 percent Monday, or $3.562, to close at $8.312.
¿ Curis Inc., of Cambridge, Mass., and Aegera Therapeutics Inc., of Montreal, entered a licensing and research agreement granting Curis exclusive worldwide rights to Aegera's skin-derived adult stem cell technologies. With licensing fees, research support and milestone payments and royalties on potential product sales, the deal is valued at more than $25 million.
¿ Discovery Partners International Inc., of San Diego, entered an exclusive licensing agreement with Abbott Laboratories Inc., of Abbott Park, Ill., for Abbott's Micro Arrayed Compound Screening technology. DPI will integrate the technology into its existing technologies to develop an advanced high-throughput screening system. Abbott will have access to the improved technology and will receive royalties on net sales. Further financial terms were undisclosed.
¿ Diversa Corp., of San Diego, said it licensed several enzymes for early stage testing of further application to The Dow Chemical Co., of Midland, Mich. Diversa received license fees associated with the enzymes and is entitled to receive royalties upon commercialization of certain products.
¿ Dyax Corp., of Cambridge, Mass., said it granted Human Genome Sciences Inc., of Rockville, Md., an exclusive license to purify HGS' B-lymphocyte stimulator protein, known as BLyS. Under the terms, HGS received a protein purification license to a family of Dyax's custom peptide ligands discovered specifically for the purification of BLyS. Dyax received a license fee and will receive commercial milestone payments, as well as royalties on final BLyS sales. In separate news, Dyax and Abgenix Inc., of Fremont, Calif., entered into a collaboration to develop new technologies for discovering and developing human antibody therapeutics. The companies will combine Abgenix's XenoMouse technology with Dyax's proprietary phage display technology to create libraries of human antibody sequences. Under the terms, the companies will share the costs of creating the antibody libraries. For any antibody product developed, each will pay reciprocal commercialization fees to the other party. Financial terms were not disclosed.
¿ EPIcyte Pharmaceutical Inc., of San Diego, appointed Christopher Clement as CEO. Clement has 20 years of operational and product development experience in the pharmaceutical and biotechnology industries. He most recently was senior vice president and chief marketing officer of the Ares-Serono Group, of Geneva, Switzerland, where he oversaw corporate marketing operations.
¿ Gene Logic Inc., of Gaithersburg, Md., and IDEC Pharmaceuticals Inc., of San Diego, entered an agreement granting IDEC a subscription to Gene Logic's GeneExpress Oncology DataSuite for use in IDEC's drug discovery programs. Financial details were undisclosed.
¿ Genzyme Transgenic Corp., of Framingham, Mass., expanded its agreement with Centocor Inc., of Malvern, Pa., to include a worldwide semiexclusive license for commercial production of tumor necrosis factor antagonists. The agreement expansion calls for a license fee payment to Genzyme of $4 million.
¿ Gliatech Inc., of Cleveland, voluntarily discontinued distribution of Adcon-L and Adcon-T/N temporarily because of a voluntary recall by the supplier of raw material used in the production of Adcon gels due to potential particulates in the raw material from the aluminized paper lid liner. The FDA has issued an import alert with respect to Adcon-L. The FDA approved Adcon-L for anti-scarring in association with lumbar surgery in May 1998. Gliatech's stock (NASDAQ:GLIA) dropped 38 percent, or $2.312, Monday to close at $3.75.
¿ IGT Pharma Inc., of Vancouver, British Columbia, said shareholders authorized the issuance of 10.734 million shares to acquire all the outstanding shares of Neurotrophic BioScience Inc., of Toronto, in a merger of equals. IGT and NTB, which announced the proposed merger in October valued then at about US$9 million, will become Prescient NeuroPharma Inc. The new company is in the process of raising $10 million privately. (See BioWorld Today, Oct. 20, 2000.)
¿ Incyte Genomics Inc., of Palo Alto, Calif., said it entered a licensing agreement with Corning Inc., of Corning, N.Y., granting Corning rights to Incyte's gene sequence databases and gene patent portfolio. Financial details were unavailable. Incyte also entered a multimillion-dollar nonexclusive licensing agreement for the development and commercialization of gene expression arrays with Agilent Technologies Inc., also of Palo Alto. The agreement gives Agilent access to Incyte cDNA clones to develop comprehensive human and animal microarrays to identify genes involved in various biological processes.
¿ Lexicon Genetics Inc., of The Woodlands, Texas, said it delivered its first installment of the LexVision database containing gene function information for potential new drug targets to Bristol-Myers Squibb Co., of New York. The delivery, made just before the end of 2000, triggered the initial quarterly payment from Bristol-Myers for its first year of access to LexVision.
¿ Matrix Pharmaceuticals Inc., of Fremont, Calif., said it completed its three-part new drug application for its anticancer agent IntraDose Injectable Gel. The filing is based on two pivotal studies in a total of 178 patients with refractory or recurrent head and neck cancer.
¿ Millennium Pharmaceuticals Inc., of Cambridge, Mass., and Roche Diagnostics Inc., a subsidiary of F. Hoffmann-La Roche Ltd., of Basel, Switzerland, entered a three-year agreement focused on the development of rheumatoid arthritis diagnostics. The collaboration will apply Millennium's proteomics technologies, and will give Roche research and development rights to select diagnostic markers and related intellectual property. Millennium will receive an undisclosed license fee, research funding, milestone payments and royalties.
¿ Neurocrine Biosciences Inc., of San Diego, said its Phase I and II studies of NBI-34060 for insomnia produced favorable results. A Phase II study of that candidate, Ambien and zopicline compared to placebo indicated that NBI-34060 produced no next-day hangover effects, while Ambien and zopiclone both produced statistically significant measures of adverse side effects of residual sedation.
¿ Novartis AG, of Basel, Switzerland, submitted an investigational new drug application for salmon calcitonin tablets for treatment of osteoporosis using the oral drug delivery technology of Emisphere Technologies Inc., of Tarrytown, N.Y. Novartis and Emisphere entered a research collaboration focused on the oral delivery technology for treatment of osteoporosis in December 1997.
¿ Qiagen Genomics Inc., of Seattle, and Genomics Collaborative Inc., of Cambridge, Mass., entered a collaboration to analyze genetic profiles of geographically distinct patient populations with known poor drug metabolism against an equal set of control patients who have reported no adverse events related to the leading metabolism enzymes. In July the companies formed an alliance to offer an integrated solution combining GCI's sample repository and database services with Qiagen's high-throughput single nucleotide polymorphism genotyping services.
¿ SciClone Pharmaceuticals Inc., of San Mateo, Calif., initiated a Phase II study of Zadaxin, its immune system enhancer, in combination with radio frequency abalation (RFA) in patients with hepatocellular carcinoma. The open-label, randomized, controlled study is designed to evaluate whether Zadaxin therapy contributes to the effectiveness of tumor therapy with RFA.
¿ Shaman Pharmaceuticals Inc., of South San Francisco, filed for Chapter 11 reorganization under federal bankruptcy law. During the proceedings Shaman will continue operations as a debtor in possession, and will pursue a plan of reorganization and restructuring of its debts.
¿ Sonus Pharmaceuticals Inc., of Bothell, Wash., began enrollment in a Phase I clinical study with S-8184, an injectable paclitaxel emulsion formulation. The dose-escalating, 25-patient safety study will involve administration of the drug as a single injection and also will test whether premedications may be eliminated.
¿ The Medicines Co., of Cambridge, Mass., filed with the SEC for a follow-on public offering of 4 million shares. TMC opened Monday at $16.953. At that price, the offering would gross $67.812 million. The company received marketing approval for its anticoagulant Angiomax in December. In August the company priced its initial public offering of 6 million shares at $16 each, raising $96 million. (See BioWorld Today, Dec. 19, 2000, and Aug. 9, 2000.)
¿ Tripos Inc., of St. Louis, said its net income for the quarter ending Dec. 31 is expected to be between a record $1.8 million and $2.2 million. Also, Tripos said its board approved a two-for-one stock split. Its stock (NASDAQ:TRPS) climbed $3 Monday, or about 15 percent, to close at $25.